Drug intelligence / Profile preview

AmyP53

Development stage: Preclinical
Lead developer: AmyPore
Modality: Peptides
Administration: Intranasal

Overview

AmyP53 is a first-in-class chimeric peptide developed by AmyPore for the treatment of neurodegenerative proteinopathies, including Alzheimer's disease and Parkinson's disease. Administered as a nasal spray, the drug targets the amyloid pores/gangliosides pathway to block the neurotoxic cascade. Its mechanism of action involves preventing amyloid oligomers from binding to gangliosides in brain cell membranes, thereby inhibiting the formation of neurotoxic pores. AmyP53 is currently in preclinical development and serves as the prototype for a platform technology that may address other protein-misfolding conditions such as diabetes, Creutzfeldt-Jakob disease, and ALS.

Other names: AmyP53AmyP-53AmyP 53

Targets

Monosialotetrahexosylganglioside (GM1) clusters in neuronal lipid rafts

Beyond the preview

Go deeper on AmyP53.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmyP53.

Explore the full profile